Enliven Therapeutics, Inc./$ELVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- Ticker
- $ELVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 67
- Headquarters
- Boulder, United States
- Website
- www.enliventherapeutics.com
ELVN Metrics
BasicAdvanced
$3.3B
-
-$1.67
0.24
-
Price and volume
Market cap
$3.3B
Beta
0.24
52-week high
$62.32
52-week low
$14.79
Average daily volume
1.6M
Financial strength
Current ratio
64.073
Quick ratio
63.213
Long term debt to equity
0.001
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-124.284
Management effectiveness
Return on assets (TTM)
-11.00%
Return on equity (TTM)
-15.31%
Valuation
Price to book
3.69
Price to tangible book (TTM)
3.69
Price to free cash flow (TTM)
-42.614
Free cash flow yield (TTM)
-2.35%
Free cash flow per share (TTM)
-1.058
Growth
Earnings per share change (TTM)
-16.46%
3-year earnings per share growth (CAGR)
-18.72%
What the Analysts think about ELVN
Analyst ratings (Buy, Hold, Sell) for Enliven Therapeutics, Inc. stock.
Analyst projections of the future price of Enliven Therapeutics, Inc. stock.
Bulls say / Bears say
In the 80 mg once-daily Phase 1b cohort, 61% of patients had achieved a major molecular response overall, and 48% had achieved one by week 24. The signal was stronger among patients treated after only one or two prior therapies. (Enliven Therapeutics)
ELVN-001 showed a generally manageable safety profile in the Phase 1 study: at the 80 mg dose, 24% had a severe or worse treatment-emergent adverse event, and thrombocytopenia was the only such event reported in more than 5% of patients. Only 6% of patients discontinued treatment because of adverse events. (Enliven Therapeutics)
Enliven reported $895.2 million in cash, cash equivalents and marketable securities at the end of June 2026, which it expects to fund operations into 2030. That gives it substantial scope to advance its CML trials without an imminent need to raise more capital. (Enliven Therapeutics)
The encouraging response figures are from an early-stage study, and only 28 patients in the 80 mg cohort were evaluable for response by week 24. Enliven still needs a larger, randomised Phase 3 trial to show that ELVN-001 compares well with existing treatments. (Enliven Therapeutics)
Enliven’s chief executive described Scemblix as the established market leader in first- and second-line CML. ELVN-001’s initial planned pivotal trial is for patients treated with one or more prior therapies, so it will have to establish a clear place against entrenched options. (Seeking Alpha)
The company has narrowed its pipeline: management said it is no longer pursuing ELVN-002 in the clinic and is not doing further discovery work to expand the pipeline. That leaves Enliven more dependent on ELVN-001 and its ability to bring future programmes forward. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
ELVN Financial Performance
Revenues and expenses
ELVN Earnings Performance
Company profitability
Upcoming events
No upcoming events
ELVN News
AllArticlesVideos
Funds containing ELVN
Fund name | Fund size | $ELVN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.21% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.21% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.